CRA provided expert reports and trial testimony in a breach of contract litigation involving the development of a novel botanical drug on behalf of the defendant. The plaintiff licensor alleged that the licensee had failed to appropriately develop the product pursuant to its contractual obligations. CRA assessed the licensee’s commercial launch plan and its investments in the development process with respect to the licensee’s “commercially reasonable efforts” obligations and the potential market for the novel product.
2022 Year in Review: Litigation
Our return to office in 2022 coincided with a year of intense activity in our dispute resolution engagements and other areas of the practice. Wins at trial...